1 . 2021

Prophylactic salpingo-oophorectomy in patients with BRCA-associated breast cancer

Abstract

BRCA1 and BRCA2 genes mutations increase the risk of breast and ovarian cancer. Primary diagnosis of ovarian cancer is a complicated task due to the lack of effective screening programs, in this regard, medical and genetic counseling of patients with a family history is one of the important steps to develop an optimal strategy for the management of patients. In this article is presented an analysis of a clinical case of a patient with bilateral metachronous breast and ovarian cancer with a detected germinal mutation 5382insc in the BRCA1 gene.

Keywords:gene BRCA1, gene BRCA2, ovarian cancer, breast cancer, medical and genetic counseling

Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
For citation: Lyubchenko L.N., Suglobova A.A., Zelenova E.E., Jordania K.I. Prophylactic salpingo-oophorectomy in patients with BRCA-associated breast cancer. Clinical and Experimental Surgery. Petrovsky Journal. 2021; 9 (1): 107-13. DOI: https://doi.org/10.33029/2308-1198-2021-9-1-107-113 (in Russian)

References

1. Kaprin A.D., Starinskiy V.V., Petrova G.V. The state of cancer care to the population of Russia in 2017. Moscow: MNIOI im. P.A. Gertsena - filial FGBU «NMITsR» Minzdrava Rossii, 2018. 236 p. ISBN 978-5-85502-237-7. (in Russian)

2. Heemskerk-Gerritsen B.A., Seynaeve C., van Asperen C.J., et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015; 107 (5).

3. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94 (18): 1365-72.

4. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62 (3): 676-89.

5. Powell C.B., Swisher E.M., Cass I., et al. Longterm follow-up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013; 129 (2): 364-71.

6. Biglia N., Sgandurra P., Bounous V.E., et al. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Cancer Med Sci. 2016; 10: 639.

7. Childers C.P., Childers K.K., Maggard-Gibbons M., et. al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017; 35 (34): 3800-6.

8. Henderson J.T., Webber E.M., Sawaya G.F. Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US), 2018 Feb. Report No. 17-05231-EF-1. U.S. Preventive Services Task Force Evidence Synthesis, formerly Systematic Evidence Reviews.

9. Kotsopoulos J., Gronwald J., Karlan B.Y., et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018; 4 (8): 1059-65.

10. Kramer L. Mixed reviews on removing fallopian tubes to prevent ovarian cancer. Can Med Assoc J. 2013; 185 (9): E391-2.

11. Rebbeck T.R., Kauff N.D., Domchek S.M. Metaanalysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101 (2): 80-7.

12. Finch A.P., Lubinski J., Moller P., et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014; 32 (15): 1547-53.

13. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009; 113 (4): 957-66.

14. Eleje G.U., Eke A.C., Ezebialu I.U., et. al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018; 8: CD012464. DOI: https://doi.org/10.1002/14651858.CD012464.pub2

15. Hoskins P.J., Gotlieb W.H. Missed therapeutic and prevention opportunities in women with BRCA-mu-tated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA Cancer J Clin. 2017; 67: 493-506.

16. D’Alonzo M., Piva E., Pecchio S., et al. Satisfaction and impact on quality of life of clinical and instrumental surveillance and prophylactic surgery in BRCA-mutation carriers. Clin Breast Cancer. 2018; Jul 26. pii: S1526-8209(18)30094-6 DOI: https://doi.org/10.1016/j.clbc.2018.07.015

17. Bacha O.M., Gregoire J., Grondin K., et al. Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer. 2012; 22 (6): 974 - 8.

18. Iavazzo C., Gkegkes I.D., Vrachnis N. Primary peritoneal cancer in BRCA carriers after prophylacticbi-lateral salpingo-oophorectomy. J Turk Ger Gynecol Assoc. 2016; 17 (2): 73-6.

19. Levine D.A., Argenta P.A., Yee C.J., et. al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003; 21 (22): 4222-7.

20. Oliver Perez M.R., Magrina J., Garcia A.T. Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: a reappraisal. Surg Oncol. 2015; 24 (4): 335-44.

21. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2019 - July 30, 2018.

22. Lakhani S.R., Manek S., Penault-Llorca F. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004; 10 (7): 2473-81.

23. Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet. 2014; 289: 241-6.

24. Bristow R.E., Powell M.A., Al-Hammadi N., Chen L., Miller J.P., Roland P.Y., et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst. 2013; 105 (11): 823-32.

25. Bristow R.E., Chang J., Ziogas A., Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol. 2013; 121 (6): 1226-34.

26. Howell E.A., Egorova N., Hayes M.P., Wisnivesky J., Franco R., Bickell N. Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol. 2013; 122 (5): 1025-32.

27. Maringe C., Walters S., Butler J., Coleman M.P., Hacker N., Hanna L., et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012; 127 (1): 75-82.

28. Sabiani L., Barrou J., Mathis J., Eisinger F., Bannier M., Lambaudie E., et al. How to manage BRCA mutation carriers? Horm Mol Biol Clin Investig. 2020; 41 (3). DOI: https://doi.org/10.1515/hmbci-2019-0065